TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04631120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Dementia Practice Unit Design
Description: * Dementia Central: monthly review of participant progress~* Dementia Mobile: monthly nurse/lay health educator visits for assessments, education and coaching~* Dementia Link: communication between Dementia Central and Dementia Mobile using the eTransX mHealth platform and HealthStream educational interface for care providers and the patient/caregiver dyad.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard clinical practices of the physician and institution including an initial assessment, Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard patient- and caregiver-centered educational material. Two phone sessions with a study nurse post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment.
Study: NCT05149638

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cosyntropin stimulation test
Description: In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cosyntropin stimulation test
Description: In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cosyntropin stimulation test
Description: In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.
Study: NCT05511779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
Study: NCT04860661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 10 ml normal saline
Study: NCT03803111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial exercise training
Description: Initial exercise training program

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initial FCM
Description: Initial intravenous iron supplementation (FCM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subsequent FCM
Description: Subsequent intravenous iron Supplementation (FCM) after 2 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subsequent exercise training
Description: Subsequent exercise training program after 2 months
Study: NCT05272124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Abductor Strengthening
Description: Elastic resisted training of Hip Abductors (5-10 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks.
Study: NCT05218733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Erector Spinae Plane Block
Description: General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive bilateral ultrasound-guided ESPB by the an experienced anesthetist in US regional blocks, with each block 20 mL of bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra thecal morphine.
Description: General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive intra thecal morphine with spinal needle 25G, 3 ml containing 300 ug preservative free morphine

Intervention type: DRUG
Group type: OTHER
Intervention: General anesthesia using intravenous fentanyl (1µgm/kg)
Description: Patients will receive general anesthesia using intravenous fentanyl (1µgm/kg)
Study: NCT04875858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProDiax-23 (PPSV23)
Description: diabetic old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed) and healthy old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProDiax-23 (PPSV23)
Description: diabetic old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed) and healthy old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed)
Study: NCT06167265

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol Tablet 100 mg
Description: Two oral doses (total daily dose of 200 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol Tablet 100 mg
Description: Two oral doses (total daily dose of 200 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: PMR Tablet 145 mg
Description: Single oral dose (total daily dose of 290 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: PMR Tablet 145 mg
Description: Single oral dose (total daily dose of 290 mg)
Study: NCT05392179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-2191
Description: Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-2191
Description: Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
Study: NCT05544578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurses Taking On Readiness Measures (N- TORM)
Description: The intervention group will be educated about household emergency preparedness via a presentation and the Korean version of a New York City community-specific booklet called Ready New York: My Emergency Plan (NYC Emergency Management, 2022). The intervention will begin with instructing the participant to start the booklet during class 1 and completing it for homework. The class content will complement the booklet and the K-HEPI. The booklet includes preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. During class 2, study personnel will check for completion of the booklets, answer any questions that the participants may have about the evacuation and communication plans and disaster kits, and facilitate group discussion to foster social support from other community members.
Study: NCT05473871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith in Action
Description: Interpersonal level: Group exercise classes offered 6 days/week (walking, cardio dance, strength training), Kickoff event~Individual level: Motivational Interviewing calls every 6 months, Health handouts on 14 topics distributed at PA classes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith in Action+
Description: Standard Faith in Action Intervention plus: 1) Health Behavior Change Workshop for FBO leaders; 2) Targeted Messaging; and 3) Empowerment Training for Promotoras

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith in Action++
Description: Enhanced Condition plus: 1) Foster community collaborations and 2) Provide maintenance support
Study: NCT06360016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreation Activity Program
Description: Students in the study group were subjected to a 24-session RAP, including entertaining games. This program was conducted by the first-name researcher, who had completed their undergraduate education in preschool education and was supported by the second and third-named researchers as assistant instructors. The 24-session program, which included rhythm, balance, and patience acquisition games, was planned according to a game theory model that primarily aimed to entertain children. The program, aimed at developing children's self-regulation skills based on fundamental reflections of the model, would consist of simple rule-based entertaining games. Before the program's application, researchers provided information about the research and program to the experimental group, and verbal consent was obtained.
Study: NCT05826678

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitor
Description: The Clinical Diabetes Educator (CDE) will follow up with the participants at Month 1 after the baseline study visit, at the study midpoint (Month 3), and at the end of the study (Month 6) to check CGM usage, including timely calibration and change adherence. At the end of the study, participants will be invited to complete a survey and participate in virtual interviews to assess changes in their health behaviors and the acceptability of CGM devices.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Finger stick glucose monitoring
Description: Participants will adhere to the standard care protocol and continue self-monitoring of blood glucose through fingersticks as per usual practice\[46\]. The Clinical Diabetes Educator (CDE) will monitor and provide follow-up to the control group participants as per the same schedule followed for the intervention group.
Study: NCT06054867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Waterjet Treatment
Description: The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System.~During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real-time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.
Study: NCT04999826

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo biospecimen collection

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05180110

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venepuncture
Description: Venous blood draw

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fingerstick
Description: Capillary blood draw
Study: NCT04590872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tolerogenic Dendritic Cell Vaccine
Description: PIpepTolDCs
Study: NCT05167500

Intervention type: DRUG
Intervention: Lorlatinib
Description: No treatment will be administered to the patient as an active treatment of this study. Only retrospective data about the patients treated in the compassion use program of Lorlatinib will be collected. The information below is related to Lorlatinib, target drug for the collection of data.~Lorviqua 25 mg film-coated tablets.The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Dosing interruption or dose reduction may be required based on individual safety and tolerability.Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily.
Study: NCT05511779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
Study: NCT05830799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Drug Interaction
Description: The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated
Study: NCT04745793

Intervention type: OTHER
Intervention: Hyperspectral and Fluobeam acquisition
Description: Once enough exposure of the operative site is achieved, an RGB (Red Green Blue) picture will be taken and the surgeon will depict the parathyroid glands on it, this picture will act as ground truth. At this point, without changing the surgical exposure, a second surgeon involved in the study will attempt once to detect the parathyroid glands intraoperatively using the HSI system and the Fluobeam® alternatively. The number and the position of the parathyroid glands visualized with each tool will be compared to the number and position of the glands previously visualized by the operating surgeon. The procedure will be repeated every time the surgeon attempts to visualize the parathyroid glands. The order of the detection tools randomized for each case will be preserved in case of repeated visualizations.

Intervention type: OTHER
Intervention: Hyperspectral and Fluobeam acquisition
Description: Once enough exposure of the operative site is achieved, an RGB (Red Green Blue) picture will be taken and the surgeon will depict the parathyroid glands on it, this picture will act as ground truth. At this point, without changing the surgical exposure, a second surgeon involved in the study will attempt once to detect the parathyroid glands intraoperatively using the HSI system and the Fluobeam® alternatively. The number and the position of the parathyroid glands visualized with each tool will be compared to the number and position of the glands previously visualized by the operating surgeon. The procedure will be repeated every time the surgeon attempts to visualize the parathyroid glands. The order of the detection tools randomized for each case will be preserved in case of repeated visualizations.
Study: NCT04654000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rheopheresis procedure
Description: rheopheresis is performed using an automated monitor (Plasauto, company HemaT) in a double-filtration cascade. Plasma purify from of high molecular weight proteins

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-apheresis
Description: Sham-apheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient.
Study: NCT05466266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICE
Description: All patients received ICE examination.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEE
Description: All patients received TEE examination.
Study: NCT05121506

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CBD and THC with GT4 technology
Description: A single topical dose of CBD and THC will be administered with GT4 technology. The material will be provided in a single use pre-filled syringe.
Study: NCT06566378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: In children pre-procedure, buzzy was placed under the armpit. The children were made before starting the application. It continued until the end of vaccination procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy (Placed in standard)
Description: In children pre-procedure, buzzy was placed on the arm. The children were made before starting the application. It continued until the end of vaccination procedure.
Study: NCT05836025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: 5mg/week of rapamycin orally for 12 weeks
Study: NCT04589130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrave 8Mg-90Mg Extended-Release Tablet
Description: Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).~Participants randomized to the control arm for the first 6 months will crossover and be administered 4 Contrave tablets a day during the second 6 months (2 tablets taken twice a day). All participants will be in the treatment group (Contrave) during the second 6 month phase of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day (2 tablets, taken twice a day) during the first 6 months of the study. These participants will crossover to treatment with Contrave for the second 6 months of the study.
Study: NCT06427252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: In the experimental group, HIPEC treatment (paclitaxel, 3000 ml of physiological saline at 43°C for 60 min) was performed on the first day after the first exploratory laparotomy and on the third day after the radical surgery for a total of 2-3 times (total amount of paclitaxel was 175 mg/m2 ), with an interval of not more than 72 h. Intravenous systemic therapy was started 3 weeks after the completion of HIPEC treatment. systemic therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: 1. Tirilizumab: 200 mg, i.v., D1, Q3W;~2. oxaliplatin: 130mg/m2, i.v., D1, Q3W;~3. Herceptin: a tri-weekly dosing regimen with an initial loading dose of 8 mg/kg followed by 6 mg/kg Q3W.~4. Tegeo: Oral administration: 40 mg per dose for BSA \<1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle D1-D14, Q3W;
Study: NCT05836025

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg/week of placebo orally for 12 weeks
Study: NCT05452980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reestablishment of the acute angle of His
Description: A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
Study: NCT06564116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of thiomersal-free hepatitis E vaccine intramuscularly at month 0, 1 and 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of licensed hepatitis E vaccine intramuscularly at month 0, 1 and 6
Study: NCT04336826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Study: NCT06419374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT05944250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spincare matrix
Description: The Spincare device, developed by Nanomedic, is the first portable tool that delivers a non-invasive, non-therapeutic electrospun, nanofibrous matrix dressing to wounds to promote healing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spincare matrix
Description: The Spincare device, developed by Nanomedic, is the first portable tool that delivers a non-invasive, non-therapeutic electrospun, nanofibrous matrix dressing to wounds to promote healing.
Study: NCT05781555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: DaRT seeds
Description: DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. The study objectives are to collect data on the general safety and efficacy of DaRT among patients who do not fit the entry criteria of existing investigational trials.
Study: NCT05306938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Wellness Visit
Description: Adolescent Wellness Visits (AWVs) are a new health service platform for reaching young adolescents with HTC and other evidence-based prevention services which are clinic-based and school-facilitated. The AWVs bundle the following health screenings, education, and counseling on: nutrition, vision, dental, mental health (depression), contraception, sexually transmitted infections, and optional HIV testing.
Study: NCT05288348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil 30 MCG Sublingual Tablet
Description: 30 microgram sublingual tablet administered using sublingual applicator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care pain treatment
Description: standard care pain treatment given in Emergency Department